Syneika and Axilum Robotics announce the installation of a new robotic system for Transcranial Magnetic Stimulation in Nantes

Cesson-Sévigné, Strasbourg, January 07th, 2015 - Syneika, specializing in the design of medical equipments dedicated to image-guided TMS and Axilum Robotics, specializing in the development of medical robots, today announced the installation of a robotic system for image-guided Transcranial Magnetic Stimulation (TMS) in the Center for Evaluation and Treatment of Pain (CETP) of University Hospital of Nantes, France.

The CETP is investigator of a multicenter, randomized, double-blind, against placebo, clinical trial, which evaluates the impact of TMS in chronic neuropathic pain.

A similar robotic system was installed previously in the CETP of Ambroise Pare Hospital, Boulogne-Billancourt (France), main investigator of the trial.

TMS applications are numerous, ranging from neuroscience research to the treatment of neurological or psychiatric diseases resistant to drug treatments, which are the subject of increasing clinical investigations.

**Syneika One** is an innovative neuronavigator, which allows to individualize treatment by integrating the patient’s brain MRI images, automatically sets targets to stimulate and offers ease of use through a productive interface.

Control functions of the robot Robotics Axilum have recently been developed. **Axilum Robotics TMS-Robot** is the first and only robot developed specifically for TMS. The hemispherical architecture of its arm is patented. It is intended to safely automate and improve the accuracy and repeatability of this non-invasive and painless brain stimulation technique, which is usually implemented manually.

This project illustrates the quality of partnership between two young French companies at the forefront of innovation in TMS market. The robotic system thus formed by the two technologies drives precisely the positioning of a heavy stimulation device through neuronavigator's interface.

« Our team is proud about the choice of our technology for this top-level clinical trial » explains Michel Berg, CEO of Axilum Robotics. « We are convinced that the robotic system driven by Syneika One is an asset for the high quality of execution sought by investigators » notes Luc Bredoux, CEO of Syneika.

**About Syneika:**
Based in Rennes (France) Syneika develops and commercializes medical equipments for individualized Transcranial Magnetic Stimulation (TMS). The R&D team of the company has 10 years experience in image-guided medical procedures. Syneika works since 2006 in collaboration with Rennes University Hospital. This union between doctors, research scientists, and Syneik, was source of patents applications and several scientific studies, including an ongoing medical study on the treatment of depressive patients by neuronavigated TMS. Syneika is ISO 13485 certified for its Quality Management System since 2010; Syneika One is a CE-marked medical device according to MDD 93/42/EEC. To date, more than 3400 TMS sessions were conducted by Syneika One neuronavigators.

http://www.syneika.com - Luc Bredoux - Tel : +33 2 22 66 55 90 - contact-us ; https://twitter.com/SYNEIKA

**About Axilum-Robotics**
Axilum Robotics is a spin-off from the ICubeMedical Robotics team and has been founded in 2011. Based on an ICube proof of concept, the company has developed and commercializes the first robot specifically designed for Transcranial Magnetic Stimulation (TMS). In a fast-growing market, Axilum Robotics’ ambition is to become the global leader in
robotic solutions for TMS. Axilum Robotics is ISO 13485 certified for its Quality Management System since 2013, has received CE mark and Health Canada licence for TMS-Robot in 2013 and benefits from an exclusive patent license agreement (US 8,303,478).

Five centers have already been equipped with Axilum Robotics’ TMS-Robot.

http://www.axilumrobotics.com - Michel Berg - Tel : +33 6 63 70 36 78 ; e-mail : info @ axilumrobotics.com